Mozart Therapeutics
Meghan Maurer is an experienced scientist with a robust background in cellular and molecular biology. Currently serving as a Scientist at Mozart Therapeutics, Inc. since April 2021, Meghan previously held the position of Associate Scientist at the same company. Prior experience includes a role as Senior Research Associate at Alpine Immune Sciences, Inc., where responsibilities encompassed advancing engineered T cell projects and conducting functional assays. Earlier in Meghan's career, research expertise was demonstrated at Cisthera, Inc. and ZymoGenetics, where in vitro assays and ligand binding studies were performed. Academic credentials include a PhD in Cell/Cellular and Molecular Biology from the University of Washington and a BA in Biochemistry from Middlebury College.
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.